Dr Kim on the Rationale For Investigating the Use of Regorafenib in mCRC

Richard Kim, MD, discusses data from a real-world investigation of long-term responses with regorafenib in patients with metastatic colorectal cancer.

Related Keywords

Richard Kim ,University Of South Florida College Medicine ,Department Of Gastrointestinal Oncology ,Flatiron Health ,Moffitt Cancer Center ,Medical Gastrointestinal Oncology ,Gastrointestinal Oncology ,South Florida College ,Cancers Symposium ,Colorectal Cancer ,Crc ,Onclive Tv ,